# Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

> **NCT02224781** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 267 (actual)

## Conditions studied

- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Melanoma
- Recurrent Melanoma
- Unresectable Melanoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Dabrafenib Mesylate
- **PROCEDURE:** Echocardiography Test
- **BIOLOGICAL:** Ipilimumab
- **PROCEDURE:** Multigated Acquisition Scan
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Trametinib Dimethyl Sulfoxide

## Key facts

- **NCT ID:** NCT02224781
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-09-08
- **Primary completion:** 2023-09-30
- **Final completion:** 2026-09-11
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224781, "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02224781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*